Gary Orris, MD
General Practice · Cumming, GANPI 1770556276
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), other and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Medtronic at 51.8% of the total. Reporting peaked in 2023 at $7,288 and has fallen 93.5% since, to $477 in 2025. Among general practice clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $40.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Lilly USA, LLC$870
- AstraZeneca$705
- GSK$569
- Supernus Pharmaceuticals, Inc.$531
- AbbVie$523
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,31050%
- Education$991%
- Other$6,18549%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 19 | $6,523 |
| Lilly USA, LLC | 48 | $870 |
| AstraZeneca | 33 | $705 |
| GSK | 13 | $569 |
| Supernus Pharmaceuticals, Inc. | 40 | $531 |
| AbbVie | 27 | $523 |
| Novo Nordisk | 10 | $440 |
| Pfizer | 20 | $332 |
| Boston Scientific | 10 | $233 |
| Novartis | 15 | $231 |
| Exact Sciences | 10 | $184 |
| Merck | 12 | $176 |
| Amgen | 8 | $149 |
| BD | 4 | $136 |
| Inspire Medical Systems, Inc. | 1 | $125 |
| Corium, LLC | 7 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Astellas Pharma US Inc | 2 | $112 |
| Bard Peripheral Vascular, Inc. | 1 | $87 |
| Eisai Inc. | 3 | $72 |
| Boehringer Ingelheim | 3 | $55 |
| Upsher-smith Laboratories LLC | 3 | $54 |
| Adlon Therapeutics L.p. | 3 | $49 |
| Aytu Biopharma, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Saluda Medical Americas, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Bioventus LLC | 1 | $21 |
| Linus Health, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$324
- RYBELSUS$244
- Inspire Upper Airway Stimulation System$125
- FARXIGA$108
- VRAYLAR$102
How this compares
$12,594 in reported general payments places this provider in the 95th percentile of 2,542 general practice providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 104 | $113,302 |
| OzempicSemaglutide | 41 | $52,168 |
| EliquisApixaban | 45 | $41,805 |
| ProliaDenosumab | 23 | $39,250 |
| FarxigaDapagliflozin Propanediol | 50 | $35,016 |
| TrulicityDulaglutide | 33 | $33,252 |
| JanuviaSitagliptin Phosphate | 21 | $22,762 |
| MyrbetriqMirabegron | 20 | $16,552 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $15,940 |
| JardianceEmpagliflozin | 11 | $12,701 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,043 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,968 |
| SynthroidLevothyroxine Sodium | 52 | $5,257 |
| Levothyroxine Sodium | 252 | $3,357 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 115 | $2,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $870 | $146,554137 claims |
| Novo NordiskOzempic | $440 | $52,16841 claims |
| PfizerEliquis | $332 | $41,80545 claims |
| AmgenProlia | $149 | $39,25023 claims |
| MerckJanuvia, Janumet | $176 | $38,70245 claims |
| AstraZenecaFarxiga | $705 | $35,01650 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $569 | $19,01030 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $16,55220 claims |
| Boehringer IngelheimJardiance | $55 | $12,70111 claims |
| AbbVieSynthroid | $523 | $5,25752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,542 general practice providers in Georgia.
Other general practice in Cumming
- Edward SchlisselMarietta$665K
- Peter VanstromTucker$424K
- Robert PauleyUnion City$155K
- Stanton McKennaAtlanta$75K
- Carlos TanGainesville$75K
- Michael BoydAugusta$67K
- Harris SiegelAtlanta$54K
- John ComisiAugusta$50K
- Jeffery BradleyLithia Springs$45K
- Ushma PatelSuwanee$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.